Skip to main content

Abbott Gets CE Mark for PCR-Based Chlamydia Test

NEW YORK (GenomeWeb News) – Abbott Laboratories said yesterday that it has received the CE Mark for a PCR-based test that can detect a new variant strain of Chlamydia trachomatis that has been found in one in five chlamydia cases in Sweden.
 
The assay, which may now be sold for clinical diagnostic use throughout the European Union, is run on Abbott’s automated m2000 real-time PCR system. Abbott said that the assay would be offered in Europe as part of its alliance with Celera.
 
Wide incidence of the mutant strain has been limited to Sweden, according to Abbott, but cases also have been reported in Ireland, Norway, Denmark, and France.
 
Abbott also sells PCR-based assays in Europe for HIV-1, hepatitis C virus, and hepatitis C viral load.

The Scan

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.